Abstract:Objective: By identifying different metabolites in the serum and clarifying the potential metabolic disorder pathways in metabolic syndrome (MS) and stable coronary artery disease patients, to evaluate the predictive value of specific metabolites based on serum metabolomics for the occurrence of MS and coronary heart disease in overweight or obese populations. Methods: This is a retrospective cross-sectional study. Patients with Metabolic Syndrome (MS group), patients with stable coronary heart disease (coronary heart disease group), and overweight or obese individuals (control group) recruited from the Central District of the First Affiliated Hospital of Zhengzhou University from 2017 to 2019 were assigned to the training set, meanwhile, the corresponding three groups of people recruited from the East District of the hospital during the same period were assigned to the validation test. The serum metabolomics profiles were determined by ultra-performance liquid chromatography-quadrupole/orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS). Clinical characteristics (age, gender, body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol (TC), triacylglycerol (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), glomerular filtration rate (eGFR), creatinine (CR)) were also collected. Based on the orthogonal partial least-squares discrimination analysis (OPLS-DA) model, the significantly changed metabolites for MS and coronary artery disease patients were screened according to variable important in projection (VIP), and the receiver operating characteristic (ROC) analysis was evaluated for the risk prediction values of changed metabolites. Results: A total of 488 subjects were recruited in this study, the training set included 40 MS, 249 coronary artery disease patients and 148 controls, the validation set included 16 MS, 18 coronary artery disease patients and 17 controls. We made comparisons of the serum metabolites of coronary artery disease vs. controls, MS vs. controls, and coronary artery disease vs. MS, and a total of 22 different metabolites were identified. The disturbed metabolic pathways involved were phospholipid metabolism, amino acid metabolism, purine metabolism and other pathways. Through cross-comparisons, we identified 2 specific metabolites for MS (phosphatidylcholine (18∶1(9Z)e/20) and pipecolic acid), 4 specific metabolites for coronary artery disease (lysophosphatidylcholine (17∶0), PC(16∶0/16∶0), hypoxanthine and histidine), and 4 common metabolites both for MS and coronary artery disease (isoleucine, phenylalanine, glutathione and LysoPC(14∶0)). Based on the cut-off values from ROC curve, the predictive value of the above metabolites for the occurrence of MS in overweight or obese populations is 100%, the predictive value for the occurrence of coronary heart disease is 87.5%, and the risk predictive value for coronary heart disease in MS patients is 82.1%. Conclusions: The altered serum metabolites suggest that MS and coronary heart disease may involve multiple metabolic pathway disorders. Specific metabolites based on serum metabolomics have good predictive value for the occurrence of MS and coronary heart disease in overweight or obese populations.

Exploring Metabolic Syndrome Serum Profiling Based on Gas Chromatography Mass Spectrometry and Random Forest Models.

Exploring Metabolic Syndrome Serum Free Fatty Acid Profiles Based on GC–SIM–MS Combined with Random Forests and Canonical Correlation Analysis

Plasma Metabolic Fingerprints for Large-Scale Screening and Personalized Risk Stratification of Metabolic Syndrome

An Augmented Model with Inferred Blood Features for the Self-diagnosis of Metabolic Syndrome.

Discovery of Metabolite Profiles of Metabolic Syndrome Using Untargeted and Targeted LC–MS Based Lipidomics Approach

Discovery and Comparison of Serum Biomarkers for Diabetes Mellitus and Metabolic Syndrome Based on UPLC-Q-TOF/MS

Multi-stage metabolomics and genetic analyses identified metabolite biomarkers of metabolic syndrome and their genetic determinants

A Non-invasive Model for Detection of Undiagnosed Metabolic Syndrome in School Children and Adolescents

Human Plasma Metabolic Profiles of Coronary Heart Disease by Gas Chromatography-Mass Spectrometry with Monte Carlo Tree Approach

Identification of Novel Biomarkers for Metabolic Syndrome Based on Machine Learning Algorithms and Integrated Bioinformatics Analysis

Plasma Metabolic Profiling and Multiclass Diagnostic Model Development for Stable Angina Pectoris and Acute Myocardial Infarction

Plasma Signature Metabolites of Dietary Fat Intake Characterize Associations with Prevalent Metabolic Syndrome

A Metabolic Profiling Strategy for Biomarker Screening by Gc-Ms Combined with Multivariate Resolution Method and Monte Carlo Pls-Da

Random Forest In Clinical Metabolomics For Phenotypic Discrimination And Biomarker Selection

Metabolic Alterations of Impaired Fasting Glucose by GC/MS Based Plasma Metabolic Profiling Combined with Chemometrics

Detection of metabolic syndrome with ATR-FTIR spectroscopy and chemometrics in blood plasma

[Risk prediction of metabolic syndrome and coronary artery disease in overweight and obese populations based on serum metabolomics]

Integrating machine learning and nontargeted plasma lipidomics to explore lipid characteristics of premetabolic syndrome and metabolic syndrome

A Method for Handling Metabonomics Data from Liquid Chromatography/mass Spectrometry: Combinational Use of Support Vector Machine Recursive Feature Elimination, Genetic Algorithm and Random Forest for Feature Selection

Serum Metabolic Profiling of Type 2 Diabetes Mellitus in Chinese Adults Using an Untargeted GC/TOFMS

Identification of free fatty acids profiling of type 2 diabetes mellitus and exploring possible biomarkers by GC–MS coupled with chemometrics